Please login to the form below

Not currently logged in
Email:
Password:

AZ's Symbicort suffers setback

AstraZeneca has been denied approval by the FDA for the use of its asthma drug Symbicort in children aged 6-11 years old

AstraZeneca has been denied approval by the US Food and Drug Administration (FDA) for the use of its asthma drug Symbicort in children aged 6-11 years old.

The company received a Complete Response Letter (CRL) from the FDA that said the company had failed to provide adequate data to establish the appropriate doses of the individual components of Symbicort, budesonide and formoterol, and to establish how the components contribute to the complete product when used in children aged 6-11 years old. AstraZeneca will send the FDA a response to the CRL in due course.

Symbicort was approved in the US for use in children over 12 years old for long-term maintenance of asthma in July 2009. In February 2009, Symbicort was approved in the US for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), such as chronic bronchitis and emphysema.

Current treatment with Symbicort is not affected by the CRL.

7th April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...

Infographics